802 articles
The National Institute on Aging outlines recent priorities in aging and Alzheimer's disease research, including budget planning and training initiatives.
A prominent longevity researcher signals skepticism about rapamycin's status as a miracle anti-aging drug. What does the evidence actually show?
A Harvard small molecule screen identified apigenin as a CD38 inhibitor, revealing how this common flavonoid raises cellular NAD levels.
Dr. Nir Barzilai presents his landmark centenarian studies and the FAST aging initiative, outlining the future of geromedicine.
Dr. Nir Barzilai outlines existing FDA-approved drugs with geromedicine potential and shares insights from decades of centenarian research.
Sinclair highlights apigenin's role in blocking CD38, the enzyme that degrades NAD+, calling the combined strategy a logical anti-aging approach.
Eric Verdin, Morgan Levine, and Bette Yin Lacroix headline a 100-talk longevity conference covering NAD biology, epigenetic aging, and lifespan extension.
A critical feasibility analysis argues that inhibiting cell division via rapamycin is fundamentally flawed as an anti-aging approach.
Longevity physician Peter Attia shares a rare transparent communication addressing trust, credibility, and responsibility to his team and patients.
A quercetin, NR, urolithin A, and alpha-lipoic acid combination boosted remaining lifespan in aged mice by 33%, even on a Western diet.
Fisetin is emerging as a top senolytic candidate, clearing senescent cells linked to aging — and strawberries are its richest dietary source.
Two popular longevity drugs show evidence of interfering with the body's response to exercise — a critical tradeoff for active users.
